The respiratory system, especially the lung, is the key site of pathological injury induced by
SARS-CoV-2 infection. Given the low feasibility of targeted delivery of antibodies into the …

The lung is the prophylaxis target against SARS-CoV-2 infection, and neutralizing
antibodies are a leading class of biological products against various infectious viral …

Multiple new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have constantly emerged, as the delta and omicron variants, which have developed …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) …

The COVID-19 pandemic represents a global challenge that has impacted and is expected
to continue to impact the lives and health of people across the world for the foreseeable …

The rapid expansion of the COVID-19 pandemic has made the development of a SARS-CoV-
2 vaccine a global health and economic priority. Taking advantage of versatility and rapid …

A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to
control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have …

Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers
who received the Moderna (mRNA-1273) or Pfizer–BioNTech (BNT162b2) vaccine against …

The effectiveness of SARS-CoV-2 vaccines and therapeutic antibodies have been limited by
the continuous emergence of viral variants and by the restricted diffusion of antibodies from …

SARS-CoV-2 infection results in viral burden in the respiratory tract, enabling transmission
and leading to substantial lung pathology. The 1212C2 fully human monoclonal antibody …